- Browse by Author
Browsing by Author "Raspollini, Maria R."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Iatrogenic pathology of the urinary bladder(Elsevier, 2018) Lopez-Beltran, Antonio; Montironi, Rodolfo; Raspollini, Maria R.; Cheng, Liang; Netto, George J.; Pathology and Laboratory Medicine, School of MedicineIntravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario.Item Inherited Forms of Bladder Cancer: A review of Lynch Syndrome and Other Inherited Conditions(Future Medicine, 2018-02) Phelan, Aaron; Lopez-Beltran, Antonio; Montironi, Rodolfo; Zhang, Shaobo; Raspollini, Maria R.; Kaimakliotis, Hristos Z.; Koch, Michael O.; Cheng, Liang; Pathology and Laboratory Medicine, School of MedicineEnvironmental factors that play a role in the urothelial carcinogenesis have been well characterized. Current research is continuously exploring potential heritable forms of bladder cancer. Lynch syndrome is a well-known inheritable disease that increases the risk for a variety of cancers, including urothelial carcinomas. Screening of patients with known Lynch syndrome is important to evaluate for development of new primary tumors. Further study may provide more information on what level of follow-up each patient needs. Recent data suggest that mismatch repair mutations confer a greater risk for urothelial cancer. Additional large patient series as well as advancement of molecular testing may provide triage for Lynch syndrome patients in regards to the frequency and type of screening best suited for individual patient.